[Sponsored] For US biotech companies developing rare disease therapies, decisions about clinical evidence, patient populations and regulatory advice can have consequences in Europe long before a marketing application is submitted.
The post FDA Alignment Is a Starting Point, Not a Rare Disease Strategy for the European Market appeared first on MedCity News.
